Finding effective treatments and ultimately

A CURE FOR FRAGILE X SYNDROME

FRAXA's Impact to Date

$
0
28,036,000

Direct Investment in Fragile X Research

Current FRAXA Funded Fragile X Research

0
5

ONGOING FRAGILE X CLINICAL TRIALS AND STUDIES

Current Clinical Trials
0
34

TEAMS ACTIVELY RESEARCHING FRAGILE X

Current Research Grants
0
4

GENE THERAPY AND PROTEIN REPLACEMENT STUDIES

Current Studies
0
28

PHARMACEUTICAL AND BIOMEDICAL PARTNERS

0
11

COUNTRIES ARE HOME TO RESEARCH TEAMS

What is Fragile X Syndrome?

Fragile X syndrome (FXS) is the most common inherited cause of autism and intellectual disabilities. It affects 1 in 4,000 boys and 1 in 6,000 girls worldwide.

Fragile X syndrome occurs when a single gene on the X chromosome shuts down. This gene makes a protein needed for normal brain development. In FXS it does not work properly, the protein is not made, and the brain does not develop as it should.

Learn more about Fragile X syndrome

How Does FRAXA Help?

FRAXA’s mission is to find effective treatments and ultimately a cure for Fragile X syndrome. We directly fund research grants and fellowships at top universities around the world. We partner with biomedical and pharmaceutical companies, large and small, to bridge the gap between research discoveries and actual treatments.

Treatments for Fragile X are likely to help people affected by autism, Alzheimer’s, and other brain disorders.

Donate to FRAXA's mission

Latest Fragile X News & Updates

View all News & Updates

National Institutes of Health Releases Fragile X Strategic Plan

FRAXA Program Coordinator, Elle Skala, and long time FRAXA supporter and previous Board Member, Mary Beth Busby, traveled to the National Institutes of Health earlier this week. The timing of this meeting was perfect because the National Institutes of Health (NIH) just released their long-anticipated Strategic Plan for Fragile X Syndrome, FXTAS, and FXPOI. It will guide federal Fragile X research funding for at least the next five years and open the door for continued funding of the Fragile X Research Centers of Excellence.
Read more

A Personal Touch to Supporting Fragile X Research

As we get closer to the holiday season and the end of the year approaches, we start to reflect on what we have accomplished throughout the year. Did we keep our New Year's Resolution? Did we spend more time with family and friends? We at FRAXA want to remind you that there is no better time than the present to make a difference. Before the year ends, you can have an impact.
Read more

Targeting Adiponectin to Treat Fragile X Syndrome

FRAXA Research Foundation has awarded a $30,000 research grant to principal investigator Brian Christie, PhD, and postdoctoral fellows Jonathan Thacker, PhD, and Luis Bettio, PhD, at the University of Victoria. They are investigating whether boosting the hormone adiponectin can effectively treat Fragile X syndrome. This project is funded in partnership with the Fragile X Research Foundation of Canada, which is providing an additional $15,000.
Read more

Upcoming Events

View full event calendar
No event found!